WARNING: We do not support Internet Explorer. It is not secure and will not work correctly. Please come back using a newer web browser.

CLSI’s Publishes Annually Updated AST Supplement M100 With Standards M02 and M07


Wayne, Pennsylvania, USAThe Clinical and Laboratory Standards Institute announces the publication of its annually updated antimicrobial susceptibility testing (AST) supplement M100—Performance Standards for Antimicrobial Susceptibility Testing, 28th ed., as well as its associated methodology standards M02—Performance Standards for Antimicrobial Disk Susceptibility, 13th ed. And M07—Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, 11th ed. This year M100 is available as part of a package with either M02 or M07, or all three documents together.

M02 covers the current recommended methods for disk susceptibility testing and criteria for quality control testing, and includes the M02 Quick Guide. M07 covers reference methods for determining minimal inhibitory concentrations of aerobic bacteria by broth macrodilution, broth microdilution, and agar dilution. M100 includes annually updated tables for M02, M07, and M11.

M100, 28th ed. Includes:

  • Revised organism nomenclature.
  • Breakpoint additions and revisions.
  • Expansion of the MCIM test for detection of metallo beta-lactamases. 

M02, 13th ed. Includes:

  • Clarified definitions for breakpoint, interpretive category, and susceptible.
  • Reorganized and clarified information for staphylococci.
  • Current recommended methods for disk susceptibility testing and criteria for quality control testing.

M07, 11th ed. Includes:

  • Photographs of growth control examples and interpretation of skipped wells.
  • Reference methods for determining minimal inhibitory concentrations of aerobic bacteria.

Some highlights for 2018 include the addition of breakpoints for ceftazidime-avibactam and dalbavancin, expansion of the mCIM test for detection of metallo beta-lactamases, and new tables and expanded recommendations for QC of beta-lactam combination agents.

In addition to publishing these three documents, on February 7, 2018 and February 8, 2018 CLSI will host the Annual AST Updates Webinar. This webinar, “CLSI 2018 AST Webinar: M100, M02, and M07 Updates,” moderated by Janet Hindler, MCLS MT(ASCP) F(AAM), Consultant, Clinical Microbiology, Los Angeles, CA and presented by Romney M. Humphries, PhD, D(ABMM), Chief Scientific Officer, Accelerate Diagnostics, Tucson, AZ and Audrey Schuetz, MD, MPH, FCAP, Associate Professor of Laboratory Medicine and Pathology, Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine and Science, Rochester, MN will focus on changes and updates to these documents, followed by a question and answer session. For more information and to register, visit clsi.org/ast2018.

For more information about M100, M02, and M07, contact Patrick McGinn at pmcginn@clsi.org or +1.484.588.5933.  

CLSI sets the standard for quality in medical laboratory testing. A not-for-profit membership organization, CLSI brings together the global laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine.  

For nearly 50 years, our members, volunteers, and customers have made CLSI a respected, transformative leader in the development and implementation of medical laboratory testing standards. Through our unified efforts, we will continue to set and uphold the standards that drive quality test results, enhance patient care delivery, and improve health care around the world.

By using CLSI standards, laboratorians can improve process quality, speed the development of standard operating procedures, and implement safer practices with greater ease and efficiency.  

← Go Back